Find clinical trials for Leukemia in Ann Arbor, MI
CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
Related conditions:
Leukemia trials near Ann Arbor, MI, USA:
inhibitor, in patients with relapsed or refractory acute myeloid leukemia (AML) as part of Phase 1. In Phase 2, assessment of ziftomenib wil...
Phase 1, Phase 2
Ann Arbor, Michigan, United States and 51 other locations
The overarching objective of this study is to use novel precision medicine strategies based on inherited and acquired leukemia-specific geno...
Phase 2, Phase 3
Detroit, Michigan, United States and 7 other locations
chemotherapy regimen for the treatment of B-cell acute lymphoblastic leukemia. Part 1 of the study will optimize the dose of study drug (rux...
Phase 2
Ann Arbor, Michigan, United States and 110 other locations
Eligible untreated patients with FLT3 acute myeloid leukemia (AML) between the ages of 18 and 70 will be randomized to receive gilteritinib ...
Phase 2
Ann Arbor, Michigan, United States and 43 other locations
The purpose of this study is to characterize the efficacy of ponatinib administered in 3 starting doses (45 mg, 30 mg, and 15 mg daily) in participan...
Phase 2
Ann Arbor, Michigan, United States and 85 other locations
This is an open-label, multicenter, Phase 1b/2 study to determine the safety and tolerability of IMGN632 and assess the antileukemia activity of IMGN...
Phase 1, Phase 2
Ann Arbor, Michigan, United States and 30 other locations
Chronic lymphocytic leukemia (CLL) is the most common leukemia (cancer of blood cells). The purpose of this study is to assess retr...
Phase 2
Detroit, Michigan, United States and 49 other locations
Ozogamicin(GO) in subjects with relapsed/refractory acute myeloid leukemia. Using a standard 3+3 design, subjects will receive once cycle of...
Phase 1
Ann Arbor, Michigan, United States and 3 other locations
with FMS-like tyrosine kinase (FLT3) mutated acute myeloid leukemia (AML) who are refractory to or have relapsed after first-line AML therap...
Phase 3
Detroit, Michigan, United States and 125 other locations
of a study drug called fedratinib in participants with myelodysplastic/myeloproliferative neoplasms (MDS/MPNs) and chronic neutrophilic leukemia...
Phase 2
Ann Arbor, Michigan, United States and 2 other locations
Clinical trials
Research sites
Resources
Legal